ClinicalTrials.gg
Not yet recruitingNCT07941921URGE-UCUpdated Nov 17, 2026

Urgency in UC Patients With or Without Mucosal Healing

An observational study in Ulcerative Colitis (Disorder), sponsored by Gerhard Rogler. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Gerhard Rogler · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
280
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Colitis, Ulcerative with a site in Switzerland — 11 open to participants now, 22 under way, 12 of them phase 3. Colitis, Ulcerative · Switzerland.

Planned enrollment
6th of 12
280 · median 260
Started
2026
with 3 others
Observational
12 of 62
4 open now
Primary completion
2027-12
later than 13 of 21 live
Registered
62nd of 62
by date

Among the 62 studies in Colitis, Ulcerative with a site in Switzerland, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2026, is one of 12 observational ones, reaches primary completion later than 13 of the 21 other live ones, and was the 62nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

11 of the 62 studies in Colitis, Ulcerative with a site in Switzerland are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Colitis, Ulcerative with a site in Switzerland, or all of them as a file.
02

Study summary

This is a prospective, single-arm, observational, multicentre study conducted at four centres in Switzerland. A total of 280 adult patients with moderately active UC (Mayo score 6-12) initiating or receiving standard-of-care treatment will be enrolled. Patients will undergo standard disease monitoring according to STRIDE II recommendations, including clinical assessment, endoscopy, histology and faecal calprotectin. In addition, anorectal manometry and rectal barostat measurements will be performed at baseline and after 12 weeks of treatment. The primary endpoint is the presence of visceral hypersensitivity, defined as a discomfort/pain threshold below 90% of maximal rectal capacity during rectal distension, in patients achieving endoscopic mucosal healing (Mayo endoscopic score 0) compared with those without mucosal healing. Secondary endpoints include anorectal motor function, histological remission (Geboes score), predictors of mucosal healing and urgency resolution, and correlations between rectal hypersensitivity and faecal calprotectin.

03

Conditions studied

  • Ulcerative Colitis (Disorder)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with moderately active ulcerative colitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years of age
  • Established diagnosis of UC
  • Moderately active UC. Disease severity determined by a Complete Mayo score of 6 to 12 and no individual sub score \<1
  • Ability to understand the treatment, willingness to comply with all study requirements and ability to provide

Exclusion criteria

Exclusion Criteria:

  • Not tolerating rectal manometry or having a severely active disease (severe acute colitis) requiring hospitalization
  • Suspicion of differential diagnosis such as: Crohn's enterocolitis, ischemic colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease, associated colitis, microscopic colitis, massive pseudopolyposis or non-passable stenosis
  • Previous total colectomy or partial colectomy
  • Antibiotics within the last week prior to Baseline, any drug at the time of enrollment, or within 30 days or 5 half-lives before enrollment
  • Acute fulminant UC and/or signs of systemic toxicity
  • History of colon/rectum
  • History or presence of any disorder that, in opinion of the investigator, could impact on patient's possibility to adhere to the protocol and protocol procedures or would confound the study result or compromise patient safety
  • Serious active infection
  • Long term use of non-steroidal anti-inflammatory drugs (NSAIDs)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
280 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with ulcerative colitis

    Adult Patients with ulcerative colitis and urgency (Mayo Score between 6-12, inclusive, with a score of at least 2 on either stool frequency or rectal bleeding, or an endoscopic sub-score of at least 2 upon endoscopic examination)

    Other: there will be no study interventional therapy as this is a single arm observational study

Interventions

  • Otherthere will be no study interventional therapy as this is a single arm observational study

    there will be no study interventional therapy as this is a single arm observational study

06

What researchers measure

Primary outcomes

  1. presence of visceral hypersensitivity

    The primary objective of the study is to test the presence of urgency according to objective parameters (anorectal motor function using anorectal manometry and validated clinical outcome parameters) in ulcerative colitis patients who achieve mucosal healing (as defined by endoscopy) after 12 weeks upon standard treatment as compared to patients who do not achieve mucosal healing.

    Time frame: 12 weeks

Secondary outcomes

  1. Urgency according to histological mucosal healing

    Urgency according to histological mucosal healing: Comparison of urgency between patients with and without histological mucosal healing after 12 weeks of standard treatment. (Units on a Scale)

    Time frame: 12 weeks

  2. Predictors of endoscopic mucosal healing:

    Evaluation of age (years) as predictor of mucosal healing (yes/no)

    Time frame: 12 weeks

  3. Predictors of endoscopic mucosal healing

    Evaluation of age at onset (years) as predictor of mucosal healing (yes/no)

    Time frame: 12 weeks

  4. Predictors of endoscopic mucosal healing

    Disease duration (years), as predictor of mucosal healing (yes/no)

    Time frame: 12 weeks

  5. Predictors of endoscopic mucosal healing

    Disease extent (procitis, left sided colitis, extensive colitis) as predictor of mucosal healing (yes/no)

    Time frame: 12 weeks

  6. Predictors of endoscopic mucosal healing

    Number of previous treatments (number) as predictor of mucosal healing (yes/no)

    Time frame: 12 weeks

  7. Urgency resolution (Urgency Numeric Rating Scale)

    Assessment of urgency resolution using the Urgency Numeric Rating Scale (1-10)

    Time frame: 12 wekks

  8. Urgency resolution (Bowel Urgency Frequency)

    Assessment of urgency resolution using Bowel Urgency Frequency or BUF ( Units on a Scale)

    Time frame: 12 weeks

  9. Urgency resolution (Sensory Detection Threshold)

    Assessment of urgency resolution using Sensory Detection Threshold or SDT ( Units on a Scale)

    Time frame: 12 weeks

07

Study locations

1 site
  • University Hospital
    Zurich, 8091, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 13 months is below that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941921
Lead sponsor
Gerhard Rogler
Responsible party
Gerhard Rogler (Prof. Dr. med Dr. phil Gerhard Rogler, University of Zurich) — Sponsor-investigator
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Gerhard Rogler, Prof
Contact
gerhard.rogler@usz.ch
+41442552401

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion